HIV patients disfigureed by their drugs

Article Abstract:

An increasing number of patients are starting to feel the side effects of taking protease inhibitors to treat HIV and Aids. Side effects of the drugs include fat accumulating in certain places, like the belly, and moving away from other areas of the body, such as the arms and legs. The development of a hump on the back of the neck is also common. It is thought that up to 60% of patients taking the protease inhibitors are affected by the side effects but only 5% may actually have any noticeable effects. Doctors are concerned that as HIV and Aids patients start to live longer that the drugs may start to show more side effects, some of which could be more dangerous than the disease in the first place. Concern is also growing that the disfigurements may actually be a result of long term suppression of the disease rather than just side effects of the drug.

Comment:

UK: Increasing number of patients are starting to feel side effects of taking protease inhibitors to treat HIV & Aids

Antiinfective Preparations NEC, Anti-infective agents

---

The truths that no Christmas card company would dare touch

Article Abstract:

The Christmas story is always presented in a sanitized way by designers of Christmas cards. These cards fail to convey the harsh realities of the Christmas story, which has close parallels with modern society, including teenage pregnancy and child abuse. The cruelty of the Christmas story makes it very real and modern. Its clear message is that God wishes to embrace everyone, even society's outcasts. This is difficult to accept for those who like to categorize everybody as being within mainstream society or outside it. Jesus showed love and forgiveness to those rejected by society, and also exposed the truth that everybody is both the agent and the victim of exclusion.

Other Commercial Printing, Greeting Cards, Social aspects, Column, Christmas

---

Shire ahead on Alzheimer's hopes

Article Abstract:

Shire Pharmaceuticals, the UK company which is co-operating with the US pharmaceuticals group Johnson & Johnson, has reported positive results in clinical trials of the Alzheimer's disease drug galantamine. Undertaken in the US, the trials slowed down the progress of the disease and brought about improvement in memory and learning ability. The drug is expected to seek regulatory approval in the UK and possibly the US by the end of the year. Shares in Shire Pharmaceuticals, a biotechnology company, rose by 10% in reaction to the news.

Comment:

Reports positive results in clinical trials of the Alzheimer's disease drug galantamine

Alzheimer Disease Controllers, Anti-Alzheimer's disease agents, Shire Pharmaceuticals

Similar abstracts:

• Abstracts: Variations on a theme. This road once led to Rome
• Abstracts: Our primitive fear of drugs. Blurred horizons will spoil Kohl's blooming landscapes
• Abstracts: Velvet revolution. It used to be the Stasi who spied on us. Today, the media does the snooping
• Abstracts: After a century, we've produced the stressed out, cooped up battery child. Welcome to Wales, ma'am
• Abstracts: Funds for the future ISA providers warn of delays

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.